l e t t e r s
An important risk in the clinical application of human pluripotent stem cells (hPSCs), including human embryonic and induced pluripotent stem cells (hESCs and hiPSCs), is teratoma formation by residual undifferentiated cells. We raised a monoclonal antibody against hESCs, designated anti-stage-specific embryonic antigen (SSEA)-5, which binds a previously unidentified antigen highly and specifically expressed on hPSCs-the H type-1 glycan. Separation based on SSEA-5 expression through fluorescence-activated cell sorting (FACS) greatly reduced teratoma-formation potential of heterogeneously differentiated cultures. To ensure complete removal of teratoma-forming cells, we identified additional pluripotency surface markers (PSMs) exhibiting a large dynamic expression range during differentiation: CD9, CD30, CD50, CD90 and CD200. Immunohistochemistry studies of human fetal tissues and bioinformatics analysis of a microarray database revealed that concurrent expression of these markers is both common and specific to hPSCs. Immunodepletion with antibodies against SSEA-5 and two additional PSMs completely removed teratoma-formation potential from incompletely differentiated hESC cultures.
HPSCs hold considerable promise as a source for cell-based therapeutics. However, such therapies carry a risk of teratoma formation by residual undifferentiated cells remaining among the differentiated products 1, 2 . Earlier reports have proposed to remove teratomas retrospectively through suicide genes and chemotherapy 3, 4 , but these methods have several caveats, including adverse side effects, drug resistance and, above all, their retrospective action. Recent approaches have focused on the prospective removal of undifferentiated cells before transplantation. An important step in this direction was the derivation of a monoclonal antibody (mAb) capable of inducing cell death in pure cultures of undifferentiated hESCs 5, 6 . Yet these studies were not extended to depleting residual teratoma-initiating cells from heterogeneous differentiated cultures.
To create a universally applicable protocol for prospective removal of residual undifferentiated cells, we sought to identify a suitable surface-marker combination for FACS-based separation. We used two mAb sources: a mouse hybridoma library raised against undifferentiated hESCs 7 and a library of commercially available mAbs (Supplementary Table 1) . We used flow cytometry to identify hESCspecific markers by analyzing mAb binding to undifferentiated hESCs and to partially differentiated cells prepared by 3-d treatment with retinoic acid or bone morphogenetic protein 4 (BMP4). One mAb from our hybridoma library was found to highly label undifferentiated hESCs and was designated anti-SSEA-5 (clone 8e11). Differentiation resulted in a 2-to 3-order-of-magnitude reduction in SSEA-5 signal, a reduction substantially greater than that of the established markers TRA-1-81 (ref. (Fig. 1a) . We confirmed anti-SSEA-5 specificity for undifferentiated cells by comparing the transcription of pluripotency genes POU5F1 (OCT3/4), NANOG and SOX2 in sorted SSEA-5 + and SSEA-5 − fractions (Fig. 1b) . In addition, we tested anti-SSEA-5 specificity to pluripotent cells in vivo by immunostaining day-6 (E6) in vitro fertilization (IVF)-derived blastocyst-stage human embryos. We found that anti-SSEA-5 labeled the inner cell mass (ICM), the group of cells from which hESCs are derived 11, 12 . This was most evident by the labeling of two ICMs in a monozygotic twin blastocyst (twinning frequently occurs during IVF 13 ) (Fig. 1c) .
To test anti-SSEA-5 binding to a range of differentiated cells, we performed immunohistochemistry staining of 12-week-old hESCderived teratomas. SSEA-5 was found to be expressed in only a subset of epithelial structures expressing SSEA-4 and epithelial-specific antigen (ESA), amounting to ~2% of the teratoma cells (Fig. 1d) . SSEA-5-expressing structures exhibited morphologies reminiscent of primordial hPSCs, suggesting teratoma stem cells 14 . To test this hypothesis, we dissociated hESC-derived teratomas to single cells followed by sorting and injection of 10 5 SSEA-5 + or SSEA-5 − cells under the kidney capsules of immunodeficient mice, a model previously shown to be conducive for teratoma formation 15 . To track tumor An antibody against sseA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells l e t t e r s progression, we used an H9 hESC clone expressing a luciferase-GFP fusion protein and monitored luciferase activity 16, 17 . We found that the SSEA-5 + cells grew rapidly, whereas the average signal from the SSEA-5 − cells remained low (P < 0.05) (Fig. 1e) . All seven SSEA-5 + transplants from three independent experiments formed large (>1 cm in maximal dimension) teratomas whereas, only 3 out of 11 SSEA-5 − transplants gave rise to smaller growths ( Table 1 ). In addition, immunohistochemistry analysis of a panel of 12 human tissues from 7-month-old fetuses did not reveal SSEA-5 expression (Fig. 1f) . Finally, SSEA-5 was not expressed on in vitro-differentiated hESC-derived hematopoietic CD34 + CD43 + precursors 18 , but rather, labeled a distinct undifferentiated SSEA-5 + CD34 − CD43 − population (Fig. 1g) . Taken together, these data provide evidence for the specificity of the anti-SSEA-5 mAb to hPSCs and suggest its capability to remove residual teratoma-initiating cells.
To determine the identity of the SSEA-5 antigen, we immunoprecipitated solubilized hESC membranes with the anti-SSEA-5 mAb followed by SDS-PAGE. Multiple bands were visualized at ~127 kDa and >190 kDa, indicating that SSEA-5 is not a single protein antigen (Supplementary Fig. 1a) . Accordingly, mass spectrometry of isolated bands was unsuccessful in identifying a single peptide (data not shown). Because hPSCs express abundant carbohydrate antigens on their surface 19 , we next tested the glycan specificity of anti-SSEA-5 by probing the surface 2a) and partially differentiated cultures produced by exposing hESCs to retinoic acid treatment for 3 d (Fig. 2c) . Tumor size (>1 cm or <1 cm) indicates maximum dimension.
a Indicates growths that did not exhibit three germ layers tissues.
l e t t e r s of glycan arrays through the Consortium for Functional Glycomics 20 . Anti-SSEA-5 was found to specifically bind all six arrayed glycans with a terminal presentation of the motif Fuc1-2Galβ1-3GlcNAcβ, also known as the H type-1 (H-1) antigen (Supplementary Fig. 1b ). Fig. 1c) . The H-1 antigen is a primitive terminal glycan capable of O-and N-linkage to surface proteins. This glycan is modifiable to other glycans, including Lewis and ABO blood group antigens 21 ( Supplementary  Fig. 2a) . Analyzing glycan expression during hESC differentiation revealed a shift in the predominant terminal glycan backbone from type 1 (e.g., Lewis(a) and H-1) to type 2 (e.g., CD15/SSEA-1/Lewis(x) and H-2) after 3 d of retinoic acid treatment (Supplementary Fig. 2a ). This glycan shift was reproduced in hESC lines HES-2 (ref. 13 and data not shown) and H7 (ref. 11), and in hiPSC line IPS(BL) (Supplementary Fig. 2b ). These findings suggest that blood group antigens exhibiting a type-1 backbone (such as H-1) are specific to undifferentiated hPSCs and are potentially replaced with glycans exhibiting a type-2 backbone during the course of differentiation.
We applied two functional in vivo assays to assess the utility of the anti-SSEA-5 mAb to remove teratoma-forming cells from hESCderived preparations. We first tested the capability of anti-SSEA-5 to separate undifferentiated hESCs spiked at a 1:100 ratio into fully differentiated cells produced through 2 weeks of retinoic acid treatment (Fig. 2a) . The population of live cells sorted (viability-sorted) from the mixture of hESCs/fully differentiated cells produced large (>1 cm in maximal dimension) teratomas in all eight replicates within 7 weeks (Fig. 2b and Table 1 ). However, when mixtures were depleted of SSEA-5 + cells (Fig. 2a) , we observed the formation of small tumors in only three out of eight replicates ( Table 1) . Quantification of luciferase activity indicated that the viability-sorted mixtures formed significantly larger growths (P < 0.05) than the SSEA-5-depleted population starting at 3 weeks (Fig. 2b) .
Second, we tested the ability of anti-SSEA-5 to remove residual teratoma-forming cells from partially differentiated cultures created by 3-d exposure to retinoic acid. From these heterogeneous cultures, populations of high SSEA-5 expression (SSEA-5-high) and of low SSEA-5 expression (SSEA-5-low) were sorted and transplanted (Fig. 2c) . Teratomas formed from both populations, but those derived from SSEA-5-high cells were significantly larger (P < 0.05) at 4 (P = 0.036) and 6 (P = 0.049) weeks compared to SSEA-5-low cells (Fig. 2d) . This difference decreased and was not significant past 6 weeks (P = 0.23). Similar to teratomas formed from viability-sorted mixtures of hESCs/fully differentiated cells (Fig. 2b) , any SSEA-5-low l e t t e r s growths exhibited tissues from the three germ layers (Fig. 2d) . Taken together, these functional assays demonstrate enrichment of hPSCs in the SSEA-5-high versus SSEA-5-low populations; however, the anti-SSEA-5 mAb is insufficient by itself to separate all residual pluripotent cells. We therefore sought to identify additional markers to be used in combination with SSEA-5 to ensure complete removal of teratomainitiating cells. Analysis of a panel of commercially available mAbs revealed five trypsin-insensitive hPSC markers (Supplementary Fig. 3a ) exhibiting substantial dynamic expression ranges during hESC differentiation: CD9, CD30, CD50, CD90 and CD200 ( Supplementary  Fig. 3b ). Of these, CD9 (ref. 25 , IPS(BL) and IPS(SH) (the latter two were prepared for this study) (Supplementary Fig. 4) . To confirm that the PSMs concurrently label undifferentiated cells, we performed multicolor flow cytometry analysis, which showed that a single population co-expressing high levels of four PSMs (CD9, CD50, CD90 and SSEA-5) decreased in proportion during differentiation from 52% to 6% at days 3 and 10 of retinoic acid treatment, respectively (Supplementary Fig. 5) .
We next performed a bioinformatics analysis to evaluate the specificity of PSM combinations for undifferentiated hPSCs. We stratified >27,000 human microarray samples, of which 120 samples represented pluripotent sources, including hESCs, hiPSCs and germ cell tumors (both seminomatous and nonseminomatous morphologies) 26, 27 . Stratification was based on CD9, CD30, CD90 and CD200 transcript levels. We were unable to include CD50, as available probes were insensitive, or SSEA-5, as this marker is a glycan. Applying high thresholds for concomitant CD9, CD30, CD90 and CD200 expression (set to expression levels as least as high as those exhibited by hPSCs) revealed that >99% of the nonpluripotent tissues did not express high levels of all four PSMs, whereas almost all pluripotent samples did (Fig. 3a,b) . This specificity was maintained with combinations of three PSMs, but declined with PSM pairs and even more with single PSMs (Fig. 3b bottom) . Immunohistochemistry of 7-month-old human fetal tissues revealed that approximately half of the analyzed organs were labeled with three or more PSMs, but labeled structures within tissues rarely overlapped (Supplementary Figs. 6 and 7) . Taken together, these results suggest that concurrent high expression of three PSMs is rarely found in nonpluripotent tissues. Still, we note that co-labeling analyses are necessary to conclude whether rare stem or progenitor populations expressing concomitant PSMs exist.
To functionally test whether three PSMs are capable of distinguishing and thereby eliminating undifferentiated from differentiated hPSCs, we sorted heterogeneously differentiated cultures generated by 3-d retinoic acid treatment with representative mAb combinations (Fig. 3c) . We found that the SSEA-5/CD9/CD90-high population formed large (>1 cm in maximal dimension) teratomas with evidence of three germ layers, whereas the SSEA-5/CD9/CD90-low population did not ( Table 1) . In agreement with these results, luciferase activity imaging revealed significant size differences between SSEA-5/CD9/CD90-high and SSEA-5/CD9/CD90-low grafts (P = 0.007 l e t t e r s at week 9) (Fig. 3d) . Notably, all growths emerging from the SSEA-5/CD9/CD90-low population exhibited histologic evidence of only epithelium and mesenchyme, and lacked evidence of structures typical of teratomas, including bone, cartilage and neural rosettes (Fig. 3e) . Similarly, we found that SSEA-5/CD50/CD200-high cells formed large teratomas, whereas SSEA-5/CD50/CD200-low cells did not ( Table 1) .
In comparison, we examined the ability of two classic hPSC markers, TRA-1-81 (ref. 8 ) and SSEA-4 (ref. 10) , to remove teratoma-initiating cells by sorting and transplanting the top 15% double-high and double-low populations. We found that both TRA-1-81/SSEA-4-high and TRA-1-81/SSEA-4-low populations formed teratomas consisting of tissues of the three germ layers ( Table 1 ) and did not show significant differences in luciferase signal (Fig. 3d) .
We demonstrate here immunodepletion using three surface-marker combinations to remove residual teratoma-initiating cells from heterogeneously differentiated hESC cultures. As the centerpiece of this technique, we highlight a mAb that we generated through hESC immunization. We chose to name this mAb anti-SSEA-5, as, similarly to SSEA-1 (ref. Notably, our findings are in line with earlier observations indicating that terminal glycan backbones differ in human and mouse PSCs 9 . We found that undifferentiated hESCs exhibit blood group antigens with a type 1 backbone (Supplementary Fig. 2a) , whereas mouse (m)ESCs are known to express blood group antigens with the type 2 backbone, such as SSEA-1 (refs. 28,29) . Upon differentiation, we observed a type 1 to type 2 backbone transition in hPSCs (Supplementary Fig. 2a ).
As it is well known that mESCs decrease the expression of blood group antigens exhibiting a type 2 backbone during embyrogenesis 29 , we hypothesize that a reciprocal switch from type 2 to type 1 backbone may occur during mESC differentiation. Our results echo a recent study that found a similar switch from globo-and lacto-to ganglio-series in glycosphingolipids during hESC differentiation 30 . Collectively, these studies suggest a major transition in glycan synthesis during differentiation.
Depletion with anti-SSEA-5 mAb alone greatly reduced the teratoma-initiation potential of partially differentiated cultures (Fig. 2) . However, complete removal was achieved only after combining SSEA-5 with two additional PSMs (SSEA-5/CD9/CD90 or SSEA-5/CD50/CD200), with the resultant formation of relatively small grafts without evidence of the three germ layers (Fig. 3) . The limited tissue repertoires exhibited by the SSEA-5/CD9/CD90-low and SSEA-5/CD50/CD200-low grafts are not consistent with populations of pluripotent cells but rather with populations of precursors committed to later developmental stages. At this point, we are unaware of any clinical hurdles that may be imposed by such embryonic precursors.
The six PSMs presented here are not meant as an exhaustive list. Identification of additional markers distinguishing pluripotent from differentiated cells could further assist in depletion of teratomainitiating cells. Within the context of our in vivo experiments, immunodepletion using anti-SSEA-5 mAb alone was insufficient to completely remove teratoma potential. This suggests that some SSEA-5-low cells may have not concluded their exit from pluripotency and therefore require detection by additional PSMs. It should also be noted that our immunodepletion approach may require optimization of the PSM panel to avoid detection and removal of desired differentiated populations in the event that they express any of the PSMs. It is our hope that antibodies against SSEA-5 and the additional PSMs would be immediately applied to advance hPSC research and to ensure the safety of patients undergoing clinical trials using hPSC derivatives.
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